Clinical trials: Neuroendocrine Tumors
Malignant Melanoma
Melanoma Image Analysis Algorithm (MIAA) Validation Study
Prospective, single-arm, cross-sectional, study to establish the effectiveness of MIAA to detect melanoma in pigmented lesions, compared to gold standard histological determination.
- Trial name
- NCT02612168
- Testing
- Melanoma Image Analysis Algorithm (MIAA)
- Where
- 7 sites in United Kingdom
- Volunteers
- 514 people
- Sponsor
- Skin Analytics Limited
Neuroendocrine Tumors
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or…
- Trial name
- GI-NETorPNET (NCT02132468)
- Testing
- fosbretabulin tromethamine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mateon Therapeutics
Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan…
- Conditions
- Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors, Ovarian Germ Cell Tumor
- Trial name
- SUR-CAN (NCT05500391)
- Testing
- Oncological Follow-up
- Where
- 3 sites in France
- Volunteers
- 88 people
- Sponsor
- Centre Oscar Lambret
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Uveal Melanoma
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic…
- Trial name
- NCT02601378
- Testing
- LXS196, LXS196 and HDM201
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
This open-label study will assess the pharmacokinetics, efficacy and safety of RO5185426 administered as 240mg tablets in previously treated patients with metastatic melanoma.
- Trial name
- NCT01107418
- Testing
- RO5185426
- Where
- 13 sites in United States, Australia
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Tumor of Pancreas
Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors.
The indications for synchronous liver resection for metastatic neuroendocrine tumors of pancreatic origin remain debated and poorly described in the literature.
- Trial name
- ReSiPaTNE (NCT05528614)
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Strasbourg, France
Melanoma
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
This study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in patients with advanced unresectable or metastatic melanoma. Each drug has shown activity in trials of patients with melanoma.
- Trial name
- NCT02300935
- Testing
- trametinib, nab-paclitaxel
- Where
- 3 sites in United States
- Sponsor
- SCRI Development Innovations, LLC
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00020540
- Testing
- recombinant CD40-ligand, recombinant flt3 ligand
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Imaging with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) is normally used to see how tumors respond to treatment. If tumors shrink after therapy, doctors continue with the same treatment.
- Trial name
- NCT01423734
- Testing
- magnetic resonance imaging (MRI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoid
Natural History of Familial Carcinoid Tumor
This study will evaluate members in families with a history of small bowel carcinoid cancer to study the natural history of those family members that have the disease, determine ways to improve early detection by performing…
- Trial name
- NCT00646022
- Testing
- [18F]-DOPA
- Where
- United States
- Volunteers
- 1,600 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Melanoma, Metastatic Melanoma
Phase II Trial of Allovectin-7® for Metastatic Melanoma
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
- Conditions
- Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer
- Trial name
- NCT00044356
- Testing
- Allovectin-7®
- Where
- 16 sites in United States
- Volunteers
- 133 people
- Sponsor
- Vical
Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors.
- Conditions
- Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2, Neuroendocrine Tumor of the Thymus Grade 1 and 2, Neuroendocrine Tumor GEP Grade 1-3
- Trial name
- Lumed (NCT02088645)
- Testing
- 177Lu-PP-F11N
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University Hospital, Basel, Switzerland
Ocular Melanoma
Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on consented subjects. The OCT is a new type of camera that takes very detailed pictures inside of the eye and deeper into eye tissues.
- Trial name
- NCT00346372
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Melanoma
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer…
- Trial name
- NCT05933577
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 165 sites in United States, Argentina and 24 more
- Volunteers
- 1,089 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Unresectable or Metastatic Melanoma
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm…
- Trial name
- NCT04768881
- Testing
- Selinexor, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 15 people
- Sponsor
- Karyopharm Therapeutics Inc
Advanced Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with…
- Trial name
- NCT02554812
- Testing
- Avelumab, Utomilumab, PF-04518600
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 409 people
- Sponsor
- Pfizer
Melanoma
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of…
- Trial name
- NCT03897881
- Testing
- mRNA-4157, Pembrolizumab
- Where
- 23 sites in United States, Australia
- Volunteers
- 267 people
- Sponsor
- ModernaTX, Inc.
Melanoma
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma.
- Trial name
- NCT02975700
- Testing
- PLX3397
- Where
- 5 sites in China, South Korea
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo Co., Ltd.